Innovative patient monitoring solutions

A world without anesthesia and respiratory-related complications

Read more

Senzime for investors

Investor event from Nov 15

We hosted a digital investor event for investors, financial analysts and media on November 15.

Latest corporate news

Press Releases

Guidelines from European Society of Anaesthesiology and Intensive Care

New European guidelines for quantitative neuromuscular monitoring

The guidelines include strong recommendations of using quantitative neuromuscular monitoring and to continue quantitative monitoring of neuromuscular blockade until a TOF ratio of more than 0.9 has been achieved.

TetraGraph enables all of this, supporting neuromuscular blockade management from start to finish.

A Swedish medical device company

Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems.

Our vision is a world without anesthesia and respiratory-related complications.

CEO Statement

Accelerating sales growth in the US and Europe, strategic partnership with global leader and acquisition in the US

Pia Renaudin

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.